AC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic Scan
By Don Nico Forbes
AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration for PI-2620, a diagnostic scan targeting neurodegenerative diseases.
The biopharmaceutical company said Wednesday that the designation was granted for clinical development across three neurodegenerative conditions: Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration.
PI-2620 is a next-generation positron emission tomography imaging agent developed as part of a research collaboration between AC Immune and LMI. It is currently in phase 3 trials for detecting Tau pathology in Alzheimer's disease, the company noted.
Tau proteins--which are involved in the stabilization of neurons--are a hallmark of several neurodegenerative disorders.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
August 28, 2024 09:44 ET (13:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks